Latest Cisplatin Stories

Canopus BioPharma: Len Rothstein, 818-980-5008 Fax. 818-980-5088 President len@canopusbiopharma.com or Investor Relations: Darrow Associates, Inc. Jordan Darrow, 631-367-1866 Fax. 631-614-3612 jdarrow@darrowir.com Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer...

LOS ANGELES, California, June 19 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. , has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models. Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at Canopus are encouraged with the discovery of this new use for CB1400 to increase efficacy and...

Sun Pharmaceutical Industries has announced that the FDA has granted approval for the abbreviated new drug application to market amifostine for injection 500mg. Amifostine is used as an adjuvant in cancer treatment. Sun Pharma's amifostine for injection will be indicated for the reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin. This generic amifostine for injection is therapeutically equivalent to MedImmune's Ethyol...

The FDA has approved Merck & Co.'s injectable version of Emend, an intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting. Emend (fosaprepitant dimeglumine) for injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic cancer chemotherapy, including high-dose cisplatin. The FDA approval for Emend...

Study may help reduce debilitating side effects of cancer treatmentA new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy. The findings could lead to the development of new approaches to combat these debilitating side effects."By increasing knowledge of what causes the nausea and vomiting that accompany chemotherapy treatment, we move closer to providing patients with...

Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND(R) (fosaprepitant dimeglumine) for Injection, a new intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (CINV). EMEND for Injection is an intravenous prodrug of the oral formulation of EMEND(R) (aprepitant), which means that when EMEND for Injection is administered, fosaprepitant is rapidly converted in the body to aprepitant. EMEND for Injection is approved for...

By Masubuchi, Yasuhiro Horie, Toshiharu Cytochrome P450 (P450) enzymes oxidize xenobiotics into chemically reactive metabolites or intermediates as well as into stable metabolites. If the reactivity of the product is very high, it binds to a catalytic site or sites of the enzyme itself and inactivates it. This phenomenon is referred to as mechanism-based inactivation. Many clinically important drugs are mechanism-based inactivators that include macrolide antibiotics, calcium channel...

By Pradhan, S C; Girish, C Silymarin, a flavonolignan from 'milk thistle' (Silybum marianum) plant is used almost exclusively for hepatoprotection and amounts to 180 million US dollars business in Germany alone. In this review we discuss about its safety, efficacy and future uses in liver diseases. The use of silymarin may replace the polyherbal formulations and will avoid the major problems of standardization, quality control and contamination with heavy metals or bacterial toxins....

By Susan Heavey WASHINGTON (Reuters) - A new drug combination to treat women with cervical cancer won U.S. approval on Thursday for severe cases when surgery or radiation may not work. The drug Hycamtin, sold by GlaxoSmithKline Plc, helped patients live about three months longer when used with the chemotherapy agent cisplatin than with cisplatin alone, the U.S. Food and Drug Administration said. Both drugs are already on the market and approved separately to treat other cancers,...

WASHINGTON (Reuters) - GlaxoSmithKline Plc's cancer drug Hycamtin won U.S. approval on Thursday to treat late-stage cervical cancer when used in combination with cisplatin in cases when surgery or radiation is not likely to work. The expanded indication also allows doctors to use the combination as a first choice, after ruling out other options, when the disease is incurable, recurrent or has spread to other organs, the U.S. Food and Drug Administration said. Hycamtin is already...